Business UpdateMay 14, 2026, 07:41 AM
Cardiol Therapeutics to Present at H.C. Wainwright BioConnect
AI Summary
Cardiol Therapeutics Inc. announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference. The company will host a Fireside Chat on May 19, 2026, at 1:30 p.m. EDT, which will be accessible via live webcast on its investor relations website. Cardiol Therapeutics is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease, with lead drug candidate CardiolRx™ in Phase III for recurrent pericarditis and CRD-38 in development.
Key Highlights
- Cardiol Therapeutics to participate in H.C. Wainwright 4th Annual BioConnect Investor Conference.
- Fireside Chat scheduled for May 19, 2026, at 1:30 p.m. EDT at NASDAQ, New York.
- Live webcast accessible via Cardiol's investor relations website; replay available for 90 days.
- Company focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease.
- Lead drug candidate, CardiolRx™, modulates inflammasome pathway activation.
- MAVERIC Program (Phase III) evaluates CardiolRx™ for recurrent pericarditis.
- ARCHER Program (Phase II) studied CardiolRx™ in acute myocarditis.
- Developing CRD-38, a novel subcutaneous drug for inflammatory heart disease.
Price Impact
More from CRDL